首页> 外文OA文献 >Poly(Glycerol Adipate-co-ω-Pentadecalactone) Spray-Dried Microparticles as Sustained Release Carriers for Pulmonary Delivery
【2h】

Poly(Glycerol Adipate-co-ω-Pentadecalactone) Spray-Dried Microparticles as Sustained Release Carriers for Pulmonary Delivery

机译:聚己二酸甘油-co-ω-戊二内酯)喷雾干燥的微粒作为肺部释放的缓释载体

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Purpose The aim of this work was to optimize biodegradable polyester poly(glycerol adipate-co-ω-pentadecalactone), PGA-co-PDL, microparticles as sustained release (SR) carriers for pulmonary drug delivery. Methods Microparticles were produced by spray drying directly from double emulsion with and without dispersibility enhancers ( L -arginine and L -leucine) (0.5–1.5%w/w) using sodium fluorescein (SF) as a model hydrophilic drug. Results Spray-dried microparticles without dispersibility enhancers exhibited aggregated powders leading to low fine particle fraction (%FPF) (28.79 ± 3.24), fine particle dose (FPD) (14.42 ± 1.57 μg), with a mass median aerodynamic diameter (MMAD) 2.86 ± 0.24 μm. However, L -leucine was significantly superior in enhancing the aerosolization performance ( L- arginine:%FPF 27.61 ± 4.49–26.57 ± 1.85; FPD 12.40 ± 0.99–19.54 ± 0.16 μg and MMAD 2.18 ± 0.35–2.98 ± 0.25 μm, L -leucine:%FPF 36.90 ± 3.6–43.38 ± 5.6; FPD 18.66 ± 2.90–21.58 ± 2.46 μg and MMAD 2.55 ± 0.03–3.68 ± 0.12 μm). Incorporating L -leucine (1.5%w/w) reduced the burst release (24.04 ± 3.87%) of SF compared to unmodified formulations (41.87 ± 2.46%), with both undergoing a square root of time (Higuchi’s pattern) dependent release. Comparing the toxicity profiles of PGA-co-PDL with L -leucine (1.5%w/w) (5 mg/ml) and poly(lactide-co-glycolide), (5 mg/ml) spray-dried microparticles in human bronchial epithelial 16HBE14o- cell lines, resulted in cell viability of 85.57 ± 5.44 and 60.66 ± 6.75%, respectively, after 72 h treatment. Conclusion The above data suggest that PGA-co-PDL may be a useful polymer for preparing SR microparticle carriers, together with dispersibility enhancers, for pulmonary delivery.
机译:目的这项工作的目的是优化可生物降解的聚酯聚己二酸甘油酯-共-ω-十五烯内酯,PGA-co-PDL,微粒作为用于肺部药物递送的缓释(SR)载体。方法使用荧光素钠(SF)作为模型亲水性药物,直接在含有和不含有分散性增强剂(L-精氨酸和L-亮氨酸)(0.5-1.5%w / w)的双重乳液中直接喷雾干燥制得微粒。结果没有分散性增强剂的喷雾干燥微粒显示出聚集的粉末,导致较低的细颗粒分数(%FPF)(28.79±3.24),细颗粒剂量(FPD)(14.42±1.57μg),质量平均空气动力学直径(MMAD)2.86 ±0.24微米然而,L-亮氨酸在增强雾化性能方面显着优越(L-精氨酸:%FPF 27.61±4.49–26.57±1.85; FPD 12.40±0.99–19.54±0.16μg和MMAD 2.18±0.35–2.98±0.25μm,L-亮氨酸:%FPF 36.90±3.6–43.38±5.6; FPD 18.66±2.90–21.58±2.46μg和MMAD 2.55±0.03–3.68±0.12μm)。与未经修饰的制剂(41.87±2.46%)相比,掺入L-亮氨酸(1.5%w / w)可以降低SF的突发释放(24.04±3.87%),二者均经历时间的平方根(Higuchi模式)。比较PGA-co-PDL与L-亮氨酸(1.5%w / w)(5 mg / ml)和聚丙交酯-co-乙交酯(5 mg / ml)喷雾干燥微粒在人支气管中的毒性在处理72小时后,上皮16HBE14o细胞系的细胞活力分别为85.57±5.44和60.66±6.75%。结论以上数据表明,PGA-co-PDL可能是用于制备SR微粒载体以及分散性增强剂用于肺部递送的有用聚合物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号